FDA grants Roche's Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer

Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) granted accelerated approval of a Perjeta (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news